• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: How Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors May Change Iron Management in End-Stage Renal Disease.

作者信息

Besarab Anatole, Szczech Lynda

机构信息

FibroGen, Inc., San Francisco, California.

出版信息

Semin Dial. 2017 Jan;30(1):29-31. doi: 10.1111/sdi.12553. Epub 2016 Oct 4.

DOI:10.1111/sdi.12553
PMID:27699882
Abstract
摘要

相似文献

1
What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: How Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors May Change Iron Management in End-Stage Renal Disease.铁治疗中平衡获益与风险时的考量有哪些？：缺氧诱导因子脯氨酰羟化酶抑制剂如何改变终末期肾病的铁管理。
Semin Dial. 2017 Jan;30(1):29-31. doi: 10.1111/sdi.12553. Epub 2016 Oct 4.
2
What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: Emerging Evidence on the Safety of Intravenous Iron in Chronic Kidney Disease.铁剂治疗中平衡获益与风险时需考虑哪些因素？：慢性肾脏病患者静脉补铁安全性的新证据
Semin Dial. 2017 Jan;30(1):22-25. doi: 10.1111/sdi.12549. Epub 2016 Sep 27.
3
What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: The Role for Newly Approved Iron Treatments.铁剂治疗中权衡获益与风险时需考虑哪些因素？新批准的铁剂治疗的作用
Semin Dial. 2017 Jan;30(1):27-29. doi: 10.1111/sdi.12551. Epub 2016 Sep 29.
4
What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: Balancing Benefits and Safety with Intravenous Iron Treatment.铁剂治疗中平衡获益与风险时的考量因素：静脉铁剂治疗中的获益与安全性平衡
Semin Dial. 2017 Jan;30(1):25-27. doi: 10.1111/sdi.12550. Epub 2016 Oct 20.
5
What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: The Benefits of Intravenous Iron.铁剂治疗中权衡获益与风险时的考量因素有哪些？：静脉铁剂的获益
Semin Dial. 2017 Jan;30(1):20-22. doi: 10.1111/sdi.12552. Epub 2016 Sep 27.
6
Iron therapy for managing anaemia in chronic kidney disease.铁剂治疗慢性肾脏病贫血。
Curr Opin Nephrol Hypertens. 2018 Sep;27(5):358-363. doi: 10.1097/MNH.0000000000000436.
7
Intravenous iron therapy in end-stage renal disease.终末期肾病的静脉铁剂治疗
Semin Dial. 2006 Jul-Aug;19(4):285-90. doi: 10.1111/j.1525-139X.2006.00174.x.
8
Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.研究用缺氧诱导因子脯氨酰羟化酶抑制剂（HIF-PHI）治疗与慢性肾脏病相关的贫血。
Expert Opin Investig Drugs. 2018 Jul;27(7):613-621. doi: 10.1080/13543784.2018.1493455. Epub 2018 Jul 12.
9
Balance of Benefit and Risk in Intravenous Iron Treatment in Chronic Kidney Disease.慢性肾脏病静脉补铁治疗的获益与风险平衡
Semin Nephrol. 2016 Mar;36(2):119-23. doi: 10.1016/j.semnephrol.2016.02.006.
10
Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.脯氨酰羟化酶抑制剂治疗慢性肾脏病贫血。
Curr Opin Nephrol Hypertens. 2019 Nov;28(6):600-606. doi: 10.1097/MNH.0000000000000554.